GLP-1 receptor agonists ameliorated colitis in mice by promoting IL-22-producing ILC3 immune cells through gut microbiota remodeling — increasing beneficial Lactobacillus reuteri and the metabolite dimethylsphingosine, which independently reduced colitis.
ILC3-dependent protectionThe anti-colitis effect of GLP-1 RAs was completely abolished in mice lacking ILC3 immune cells, proving these cells are essential for the protective mechanism
What the researchers found
GLP-1RAs ameliorated DSS-induced colitis in both wild-type and T/B-cell-deficient mice via ILC3-dependent IL-22 production. Effect abolished in ILC3-deficient mice. GLP-1RAs increased Firmicutes/Proteobacteria (especially L. reuteri) and decreased pathogenic Staphylococcus. The metabolite DMS was enriched and independently ameliorated colitis while promoting IL-22+ILC3s.
Why it matters
This study provides a mechanistic explanation for the anti-inflammatory effects of GLP-1 drugs beyond diabetes. It reveals a gut microbiome-metabolite-immune cell axis that could explain why diabetic patients on GLP-1 RAs may have fewer inflammatory bowel complications and suggests a new therapeutic application for these widely used peptide drugs.
The numbers in context
GLP-1RAs worked in both wild-type and T/B-cell-deficient mice, proving the mechanism is through innate immunity (ILC3s), not adaptive immunity.
How the study worked
Animal study using DSS-induced colitis in wild-type, T/B-cell-deficient, and ILC3-deficient (RORγtgfp/gfp) C57BL/6 mice. GLP-1RA treatment followed by microbiome analysis (16S rRNA), untargeted metabolomics (GC/LC-MS), and immune cell profiling. DMS was independently tested for anti-colitis effects.
Who was studied
Wild-type and T/B-cell-deficient mice with DSS-induced colitis
What this study cannot tell us
Mouse colitis model (DSS-induced) doesn't fully replicate human IBD. The microbiota-DMS-ILC3 axis is correlative — direct causation between each step needs further validation. Specific GLP-1 RA used and dosing may not directly translate to human clinical scenarios. No human clinical data.
How to read the evidence
Rated moderate: well-designed mechanistic animal study using multiple knockout models and metabolomics, but no human clinical validation.
When this study was published
Published in 2024. Addresses the hot topic of GLP-1 RA effects beyond metabolic disease.
The bigger picture
As millions of people take GLP-1 drugs for diabetes and obesity, understanding their effects on gut immunity and the microbiome is increasingly important. This study suggests GLP-1 drugs may have genuine therapeutic potential for inflammatory bowel disease — a connection that could benefit the many patients who have both conditions.
Questions still open
- Do IBD patients on GLP-1 RAs for diabetes experience fewer disease flares?
- Could DMS supplementation alone provide anti-inflammatory benefits without GLP-1 RA treatment?
- Are the microbiome changes sustained after GLP-1 RA discontinuation?
Common questions
Can Ozempic-type drugs help with inflammatory bowel disease?
How do GLP-1 drugs affect gut bacteria?
Read the original research
GLP-1 receptor agonists alleviate colonic inflammation by modulating intestinal microbiota and the function of group 3 innate lymphoid cells.
Immunology, 172(3), 451-468
Citation
Sun, Hanxiao; Shu, Jie; Tang, Jupei; Li, Yue; Qiu, Jinxin; Ding, Zhaoyun; Xuan, Binbin; Chen, Minghui; Gan, Chenxin; Lin, Jinpiao; Qiu, Ju; Sheng, Huiming; Wang, Chuanxin. (2024). GLP-1 receptor agonists alleviate colonic inflammation by modulating intestinal microbiota and the function of group 3 innate lymphoid cells.. Immunology, 172(3), 451-468. https://doi.org/10.1111/imm.13784